Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | RET L629P RET D631_R635delinsG RET V637R |
Therapy | Pralsetinib |
Indication/Tumor Type | medullary thyroid carcinoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
RET L629P RET D631_R635delinsG RET V637R | medullary thyroid carcinoma | predicted - sensitive | Pralsetinib | Case Reports/Case Series | Actionable | In a Phase I trial, a patient with medullary thryoid cancer harboring RET D631_R635delinsG, L629P, and V637R demonstrated a partial response, with maximal tumor reduction of 47% at 10 months, following treatment with Gavreto (pralsetinib) (PMID: 29657135; NCT03037385). | 29657135 |
PubMed Id | Reference Title | Details |
---|---|---|
(29657135) | Precision Targeted Therapy with BLU-667 for RET-Driven Cancers. | Full reference... |